| Rhodium‐Catalyzed Directed Sulfenylation of Arene C H Bonds Y Yang, W Hou, L Qin, J Du, H Feng, B Zhou, Y Li Chemistry–A European Journal 20 (2), 416-420, 2014 | 184 | 2014 |
| Structure-based discovery and development of a series of potent and selective bromodomain and extra-terminal protein inhibitors J Hu, CQ Tian, MS Damaneh, Y Li, D Cao, K Lv, T Yu, T Meng, D Chen, ... Journal of Medicinal Chemistry 62 (18), 8642-8663, 2019 | 45 | 2019 |
| Bioorthogonal chemistry: Optimization and application updates during 2013–2017 LH Qin, W Hu, YQ Long Tetrahedron Letters 59 (23), 2214-2228, 2018 | 35 | 2018 |
| Potent and selective mitogen-activated protein kinase kinase 1/2 (MEK1/2) heterobifunctional small-molecule degraders J Hu, J Wei, H Yim, L Wang, L Xie, MS Jin, M Kabir, L Qin, X Chen, J Liu, ... Journal of medicinal chemistry 63 (24), 15883-15905, 2020 | 31 | 2020 |
| Targeted degradation of PRC1 components, BMI1 and RING1B, via a novel protein complex degrader strategy KS Park, L Qin, M Kabir, K Luo, B Dale, Y Zhong, A Kim, GG Wang, ... Advanced Science 10 (10), 2205573, 2023 | 12 | 2023 |
| Discovery and synthesis of 6, 7, 8, 9-tetrahydro-5H-pyrido [4, 3-c] azepin-5-one-based novel chemotype CCR2 antagonists via scaffold hopping strategy LH Qin, ZL Wang, X Xie, YQ Long Bioorganic & Medicinal Chemistry 26 (12), 3559-3572, 2018 | 11 | 2018 |
| Multi-omics characterization of WNT pathway reactivation to ameliorate BET inhibitor resistance in liver cancer cells Y Liu, M Xue, D Cao, L Qin, Y Wang, Z Miao, P Wang, X Hu, J Shen, ... Genomics 113 (3), 1057-1069, 2021 | 6 | 2021 |
| Pharmacophore model-based design and synthesis of new structure small molecule CCR2 inhibitors L Qin, X Li, Z Wang, W Yao, H Wang, X Xie, Y Long Acta Chimica Sinica 73 (7), 679, 2015 | 2 | 2015 |
| Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader M Kabir, L Qin, K Luo, Y Xiong, RA Sidi, KS Park, J Jin Journal of Medicinal Chemistry 67 (8), 6880-6892, 2024 | 1 | 2024 |
| New compounds for the treatment of alzheimer's disease B Zhang, J Jin, HU Kaniskan, QIN Lihuai, M Wang, A Li, KJ Brennand, ... US Patent App. 18/249,829, 2024 | | 2024 |
| A potent and selective ENL degrader suppresses oncogenic gene expression and leukemia progression Z Xue, L Qin, H Xuan, K Luo, M Huang, L Xie, Y Su, L Xu, J Harsh, B Dale, ... Science Advances 10 (35), eado1432, 2024 | | 2024 |
